NPS: Medical Consequences Associated with Their Intake.
Fabrizio Schifano, Laura Orsolini, Duccio Papanti, John Corkery
Current Topics in Behavioral Neurosciences 2017 DOI: 10.1007/7854_2016_15 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Drug misuse Hallucinogenic drugs Hallucinogens Novel psychoactive substances Phenethylamines Psychiatric disturbances Synthetic cannabimimetics Synthetic cathinones |
| Key findings | The authors report that over 500 novel psychoactive substances had been reported by the end of 2014, with synthetic cathinones, synthetic cannabinoids, and psychedelics/phenethylamines being the most numerous. They argue that health professionals must be aware of NPS effects and toxicity, and that evidence-based, index molecule-focused treatment strategies remain to be identified. |
Abstract
Over the last decade, the 'traditional' drug scene has been supplemented - but not replaced - by the emergence of a range of novel psychoactive substances (NPS), which are either newly created or existing drugs, including medications, now being used in novel ways. By the end of 2014, in excess of 500 NPS had been reported by a large number of countries in the world. Most recent data show, however, that synthetic cathinones, synthetic cannabinoids, and psychedelics/phenethylamines account for the largest number of NPS.The present chapter aims at providing an overview of the clinical and pharmacological issues relating to these most popular NPS categories. Given the vast range of medical and psychopathological issues associated with the molecules here described, it is crucial for health professionals to be aware of the effects and toxicity of NPS. A general overview of the acute management of NPS adverse events is provided as well, although further studies are required to identify a range of evidence-based, index molecule-focused, treatment strategies. The rapid pace of change in the NPS online market constitutes a major challenge to the provision of current and reliable scientific knowledge on these substances.
Citations in the library
Cited by 8
- New/emerging psychoactive substances and associated psychopathological consequences Psychological Medicine July 22, 2019
- Substance-related exogenous psychosis: a postmodern syndrome CNS Spectrums June 25, 2020
- New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review. Experimental Neurology May 1, 2021
- The Bridge Between Classical and “Synthetic”/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective Frontiers in Psychiatry November 20, 2019
- Psychonauts’ psychedelics: A systematic, multilingual, web-crawling exercise European Neuropsychopharmacology April 13, 2021
and 3 more in the library
Cites 50
- Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin Synapse 2000
- High-potency cannabis and the risk of psychosis The British Journal of Psychiatry November 30, 2009
- The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator Science February 13, 2009
- Prediction of Psilocybin Response in Healthy Volunteers PLoS One February 17, 2012
- Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. Journal of Medical Toxicology March 1, 2012
and 45 more in the library